Microdosing and customization Microdosing refers to using smaller or fractional doses, which are lower than therapeutic doses
Tirzepatide is also available as a once-weekly injection
Almost 40% of GLP-1 patients are new to the practice
Weight loss: Participants taking GIP/GLP-1 RA achieved significant weight loss [-4.8 kg (5 mg), -8.7 kg (10 mg) and -11.3 kg (15 mg)], as did those taking dulaglutide [-2.7 kg (1.5mg)], compared to placebo (-0.4 kg)
However, the company's formal terms of service state that services are available in certain states and territories, and advise prospective users to contact customer service for current availability
While the exact causes of NAION are not fully understood, it has been associated with various risk factors, including diabetes, hypertension, and high cholesterolconditions that many patients taking semaglutide may already have